Psychiatric disorders and Nesfatin-1<p>Psikiyatrik hastalıklar ve Nesfatin-1
Keywords:
Nesfatin-1, Pscyhiatric disorders, Depression, Antidepressant, Weight gainAbstract
Nowadays psychiatric disorders is complex group of diseases that many factors play a role in the etiology and prevalence of it's very higher. Neurotransmitters levels such as serotonin norepinefrin and dopamine in the brain is changed in case of illness. For instance Neurotransmitters such as serotonin, norepinefrin and dopamine is decreased in depression and dopamine is increased in schizophrenia. Many of the antidepressants drugs that used in the treatment of depression leads to weight gain in patients. Nesfatin-1 is expressed that recently discovered, being an anorexigenic peptid and derived NEFA / nukleobindin2 (NUCB2) in the brain's stress-related field. Plasma nesfatin-1 levels were found to be very high psychiatric patients than normal people with. Peptids' brings to mind the idea that may be important in the prognosis of the disease which the decreased of the level of hormone following treatment process and high in case of illness. It's will provide a better understanding of the prognosis of the disease that can also be explained the effect of these hormones under stress in this disease. In future studies, to understand the antidepressants effect of nesfatin-1 the important molecular mechanisms related with the nesfatin-1 receptor should be necessary to define. In light of recent studies, it is thought that nesfatin-1 could be a important antidepressant drug in the near future.
Özet
Psikiyatrik hastalıklar günümüzde prevalansı çok yüksek olan etiyolojisinde birçok faktörün rol oynadığı yaygın ve kompleks bir hastalık grubudur. Hastalık durumunda beyinde serotonin, norepinefrin, dopamin gibi nörotransmitterlerin düzeyleri değişmektedir. Örneğin depresyonda serotonin, norepinefrin ve dopamin azalmaktayken; şizofrenide ise dopamin artmaktadır. Major depresyon tedavisinde kullanılan antidepresan ilaçların çoğu hastalarda kilo alımına yol açmaktadır. NEFA/nukleobindin2 (NUKB2)'den kaynaklanan son yıllarda keşfedilen anoreksijenik bir peptid olan nesfatin-1, beynin stresle alakalı alanlarında bulunmaktadır. Psikiyatrik hastalarda normal insanlara kıyasla plazma nesfatin-1 düzeyi çok yüksek bulunmuştur. Hastalık durumunda yüksek iken, tedavi sürecini takiben hormon seviyesinin düşmesi peptidin hastalığın prognozunda önemli olabileceği fikrini akla getirmektedir. Bu rahatsızlıklarda stres altında bu gibi hormonların etkilerinin açıklanması hastalığın prognozunun daha iyi anlaşılmasını sağlayacaktır. Gelecek çalışmalarda, nesfatin-1'in antidepresif etkisini anlamak için; nesfatin-1 reseptörleri ile ilgili önemli moleküler mekanizmaların tanımlanması gerekmektedir. Son yapılan çalışmaların ışığında, nesfatin-1'in yakın gelecekte önemli bir antidepresan ilacı olabileceği düşünülmektedir.
Downloads
Metrics
References
Akabayashi, A., Koenig, J.I., Watanabe, Y., et al. (1994). Galanin-containing neurons in the paraventricular nucleus: a neurochemical marker for fat ingestion and body weight gain. Proc Natl Acad Sci USA, 91(22): 10375-10379.
Algul, S., Erman, F., Kara, B., Kara M., Erman, O. (2013). Major depresif hastalarda kısa süreli Depresyon tedavisinin nesfatin-1, nitrik oksit ve grelin düzeylerine etkileri. F Ü Sağ Bil Tıp Derg, 27(2): 69-73.
Ari, M., Ozturk, O.H., Bez, Y., Oktar, S., et al. (2011). High plasma nesfatin-1 level in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol Psychiatry, 35(2): 497– 500.
Appelhans, B.M., Whited, M.C., Schneider, K.L., et al. (2012). Depression severity, diet quality, and physical activity in women with obesity and depression. J Acad Nutr Diet, 112(5): 693- 698.
Baldwin, D., Rudge, S. (1995). The role of serotonin in depression and anxiety. Int Clin Psychopharmacol, 9(4): 41-45.
Bandelow, B. (2003). Epidemiology of depression and anxiety, In: Kasper S, Boer JA and Sisten JM, Handbook of Depression and Anxiety. Newyork: 49-68.
Bloem., B., Xu, L., Morava, E., et al. (2012). Sex specific differences in the dynamics of cocaine and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls. Neuropharmacology 62: 297-303.
Brailoiu, G.C., Dun, S.L., Brailoiu, E., et al. (2007). Nesfatin-1: Distribution and Interaction with a G Protein-Coupled Receptor in the Rat Brain. Endocrinology, 148(10):5088-5094.
Bray, G.A. (2000). Afferent signals regulating food intake. Proc Nutr Soc, 59(3): 373-384.
Ceylan, M.E., Oral, E.T. (2001). Duygudurum bozuklukları, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri Kitabı. 4. Cilt, Birinci Baskı, İstanbul, 72-135.
Bonnet, M.S., Pecchi, E., Trouslard, J., et al. (2009). Central nesfatin-1 expressing neurons are sensitive to peripheral imflammatory stimulus. J Neuroinflammation, 6: 27.
Caberlotto, L., Fuxe, K., Overstreet, D.H., et al. (1998). Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res, 59(1): 58-65.
Chaki, S., Okubo, T. (2007). Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders. Curr Top Med Chem, 7(11): 1145–1151.
Domschke, K., Dannlowski, U., Hohoff, C., et al. (2010). Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol, 20(5):301–309.
Geiselman, P.J. (1996). Control of food intake. A physiologically complex, motivated behavioral system. Endoc Metab Clin North Am, 25(4): 815-829.
Goebel, M., Stengel, A., Wang, L., et al. (2009). Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci Lett, 452(3): 241–246.
Havel, P.J. (2002). Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol, 13(1): 51–59.
Havel, P.J. (2004). Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 53(1): 143-151.
Jéquier, E. (2002). Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci, 967: 379- 388.
Kappeler, L., Zizzari, P., Grouselle, D., et al. (2004). Plasma and hypothalamic peptide-hormone levels regulating somatotroph function and energy balance in fed and fasted states: a comparative study in four strains of rats. J Neuroendocrinol; 16(12): 980-988.
Kayaalp, O. (2009). Rasyonel Tedavi Yönünden Tıbbi Farmakoloji I, Pelikan Yayıncılık, Ankara, 700.
Kırlı, S. (2000). Depresyonun Biyolojik Oluşumu ve Farmakolojik Tedavisi, Roche, Bursa.
Kranz, G.S,. Kasper, S., Lanzenberger, R. (2010). Reward and the serotonergic system. Neuroscience, 166(4): 1023–35.
Kojima, M., Hosoda, H., Date, Y., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762): 656-660.
Konczol, K., Bodnar, I., Zelena, D., et al. (2010). Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem Int, 57(3): 189–197.
Küey, L. (1998). Birinci basamakta depresyon: tanıma, ele alma, yönlendirme. Psikiyatri Dünyası, 2(1): 5-12.
Lee, Y.S. (2009). The role of leptin-melanocortin system and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore, 38(1): 34-11.
Lucki, I. (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry, 44(3): 151- 162.
Maes M, Meltzer HY, (2000) The serotonin hypothesis of major depression, Psychopharmacology: The Fourth Generation of Progress online. FE Bloom, D Kupfer (Ed).
Mann, J.J. (1999). Role of the serotonergic sysem in the pathogenesis of amjor depression and suicidal behaviour. Neuropsychopharmacology, 21(2): 99-105.
Merali, Z., Cayer, C., Kent, P., et al. Nesfatin‐1 increases anxiety‐ and fear‐related behaviors in the rat.
Psychopharmacology (Berl), 2008; 201(1): 115-123.
Morley, J.E., Levine, A.S., Yim, G.K., et al. Opioid modulation of appetite. Neurosci Biobehav Rev 1983; 7(2): 281–305.
Nonogaki, K., Ohba, Y., Sumii, M., et al. (2008). Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5‐HT2C receptors and induce anorexia via a leptin‐independent pathway in mice. Biochem Biophys Res Commun, 372(1): 186-1890.
Oh-I, S., Shimizu, H., Satoh, T., et al. (2006). Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature;, 443(7112): 709-712.
Ogiso, K., Asakawa, A., Amitani, H., et al. (2011). Plasma nesfatin-1 concentrations in restricting- type anorexia nervosa. Peptides, 32(1): 150-153.
Okere, B., Xu, L., Roubos, E.W., et al. (2010). Restraint stress alters the secretory activity of neurons co-expressing urocortin-1, cocaine- and amphetamine-regulated transcript peptide and nesfatin-1 in the Mouse Edinger-Westphal nucleus. Brain Res, 1317: 92-99.
Patten, S.B., Williams, J.V., Lavorato, D.H., et al. (2011). Weight gain in relation to major depression and antidepressant medication use. J Affect Disord, 134(1-3): 288-293.
Rao, T.L., Kokare, D.M., Sarkar, S., et al. (2003). GABA ergic agents prevent alpha-melanocyte stimulating hormone induced anxiety and anorexia in rats. Pharmacol Biochem Behav, 76(3- 4): 417-423.
Rogers, J., Agius, M. (2012). Bipolar and unipolar depression. Psychiatr Danub; 24(1): 100-105.
Rotzinger, S., Lovejoy, D.A., Tan, L.A. (2010). Behavioral effects of neuropeptides in rodent models ofdepression and anxiety. Peptides, 31(4): 736–56.
Shimizu, H., Inoue, K., Mori, M. (2007). The leptin-dependent and-independent melanocortin signaling system: regulation of feeding and energy expenditure. J Endocrinol, 193(1): 1-9.
Shimizu, H., Oh-I, S., Hashimoto, K., et al. (2009). Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology, 150(2): 662- 671.
Stengel, A., Goebel, M., Wang, L., et al. (2009). Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology, 150 (11): 4911-4919.
Stengel, A., Taché, Y. (2010). Nesfatin-1 role as possible new potent regulator of food intake. Regul Pept, 163(1-3): 18-23.
Stengel, A., Goebel-Stengel, M., Wang, L., et al. (2012). Nesfatin-1(30-59) but not the N- and C- terminal fragments, nesfatin-1(1-29) and nesfatin-1(60-82) injected tracerebroventricularly decreases dark phase food intake by increasing inter-meal intervals in mice. Peptides, 35(2): 143-148.
Tamam, L., Zeren, T. 2002Depresyonda Serotonerjik Düzenekler. Klinik Psikiyatri, 5(4): 11-18.
Tsuchiya, T., Shimizu, H., Yamada, M., et al. (2010). Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol, 73(4): 484-490.
Uğur, M. (2008). Duygudurum bozuklukları. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri, Sempozyum Dizisi, 62: 59-84.
Valassi, E., Scacchi, M., Cavagnini, F. (2008). Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis, 18(2): 158-168.
Van Praag, H.M. (1984). Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol Bull, 20(3): 599-602.
Yüksel, N. (2000). Birinci basamakta depresyon tanı ve tedavi. Ankara, Çizgi tıp yayınevi.
Yüksel, N. (2005). Psikofarmakoloji, Bilimsel Tıp Yayınevi, Ankara, 175.
Yüksel, N. (2006). Ruhsal Hastalıklar. MN Medikal Nobel, Ankara, 1250.
Yoshida, N., Maejima, Y., Sedbazar, U., et al. (2010). Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis. Aging, 2(11): 775-784.
Yosten, G.L., Samson, W.K. (2009). Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol, 297(2): 330-336.
Downloads
Published
How to Cite
Issue
Section
License
Authors can retain copyright, while granting the journal right of first publication. Alternatively, authors can transfer copyright to the journal, which then permits authors non-commercial use of the work, including the right to place it in an open access archive. In addition, Creative Commons can be consulted for flexible copyright licenses.
©1999 Creative Commons Attribution-ShareAlike 4.0 International License.
